Safety and Efficacy of Talampanel in Glioblastoma Multiforme

- Glioblastoma Multiforme
- Completed

Study Title: Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Teva Identifier: IXR-207-21-189 / NABTT 0304

ClinicalTrials.gov Identifier: NCT00267592

Study Status: Completed

Trial Condition(s): Glioblastoma Multiforme

Interventions: Drug: Talampanel | Radiation: Radiation Therapy (RT) 5 days a week + | Drug: temozolomide(TMZ) 75mg | Drug: adjuvant TMZ 200mg

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 18 Years and older

Trial Duration: 12/01/2005 - 02/01/2011

Phase: Phase 2

Study Type

Interventional